Metabolic & Body Composition
Retatrutide
Triple agonist GIP/GLP-1/Glucagon, the most advanced in its class. In phase 2 trials, it achieved up to 24% weight loss, surpassing semaglutide and tirzepatide.
Also known as: LY3437943
Specifications
| Research area | Metabolic & Body Composition | ||
|---|---|---|---|
| Half-life | ~6 days | ||
| Molecular weight | 4769.5 Da | ||
| Amino acid residues | 39 | ||
| CAS number | 2381272-90-6 | ||
| Formula | 39 AA + C₁₈ fatty diacid conjugate | ||
| Sequence | 39 aa lipidated peptide (C₁₈ fatty diacid at Lys²⁰) — abbreviated | ||
| Designation | LY3437943 — triple GLP-1R / GIPR / GCGR co-agonist | ||
Pharmacokinetics
| Half-life | ~6 days | ||
|---|---|---|---|
| T-max | 24–72 h | ||
| Bioavailability | ~50–60% (SC) | ||
| Route | Subcutaneous (research use) | ||
Receptor targets
| GLP-1R | Incretin / appetite suppression | ||
|---|---|---|---|
| GIPR | Glucose-dependent insulinotropic | ||
| GCGR (glucagon) | Energy expenditure ↑ | ||
Signalling cascade
- Triple receptor binding
- Central appetite ↓
- Insulin sensitization
- Glucagon-driven thermogenesis
- Visceral adiposity ↓
Research areas
- Mechanism of action
- Triple agonist of GIP, GLP-1, and glucagon receptors. Simultaneously reduces caloric intake via central GLP-1 and GIP pathways, increases energy expenditure through glucagon receptor activation, and modulates hepatic glucose output. Represents the first triple incretin approach in clinical-stage research.
- Reported research ranges
- 0.5–12 mg subcutaneously weekly (in clinical research phase).
- Reported adverse effects
- Nausea, vomiting, diarrhea, constipation. Profile similar to GLP-1 agonists.
- Storage and handling
- Store at 2–8 °C.
Research focus
- Triple incretin receptor agonism (GIP / GLP-1 / glucagon)
- Caloric intake regulation via central appetite pathways
- Energy expenditure augmentation through glucagon receptor
- Adipose tissue metabolism and visceral fat reduction models
- Glucose homeostasis and hepatic insulin sensitivity
Overview
Retatrutide is a research peptide that acts as a triple agonist of the GIP, GLP-1, and glucagon receptors. This compound has been the subject of numerous studies in preclinical models, where its potential to influence metabolism, fat loss, and appetite regulation is being investigated. Its combined action on these receptors makes it a promising area of interest for metabolic research.
Researchers are studying Retatrutide to gain a better understanding of how these receptors interact and affect metabolic processes in the body. The exploration of Retatrutide may provide new insights into weight management and the development of research into metabolic disorders, highlighting its significance in the field of biomedicine.
Synedica formulation
Synedica publishes a formulation record and batch certificates for this compound.
This material is published for scientific and educational reference. It is not medical advice, not a treatment recommendation, and not an offer to sell. Compounds discussed are for research and laboratory use only.
← All compounds